Role of digital health in the personalized management of heart failure due to Fontan failure: a case report
Abstract
Background: Heart failure (HF) represents a major cause of morbidity and mortality in patients with Fontan circulation. Chronic venous congestion, impaired preload, and limited cardiac output reserve make clinical assessment and intermittent invasive evaluations insufficient to capture early haemodynamic deterioration. Pharmacological treatment lack of robust evidence in this subgroup of patients. In this challenging setting, implantable invasive haemodynamic monitoring systems may provide continuous, real-life information capable of guiding personalized HF management.
Case summary: A 26-year-old Fontan male developed protein losing enteropathy and recurrent hospitalizations for decompensated heart failure. Therefore, the patient was candidate to heart transplantation. Over time, episodes of acute HF increased with an escalating requirement of dosage of diuretics. At 22 years of age, another episode of acute decompensated HF prompted a catheter-based intervention with Fontan conduit re-dilatation and re-fenestration with an Atrial Flow Regulator (AFR) implant, and a pulmonary artery pressure monitoring system (CardioMEMS™) was deployed to telemonitor pulmonary artery pressures and adjust the diuretic therapy accordingly. Up to date, 4 years from the intervention, the use of this remote monitoring system was feasible and effective in tailoring medical therapy to prevent further hospitalizations for acute HF. The patient is in clinical follow-up with regular controls.
Discussion: Systems allowing continuous or repeated assessment of haemodynamic status in real-life conditions may support personalized treatment adjustments, improve symptom control, and potentially reduce HF-related hospitalizations in patients with failing Fontan circulation.
Related
- Personalized Remote Patient Management in Heart Failure : From Implanted Hemodynamic Monitoring Toward an Artificial Intelligence-Supported Adaptive Care Cycle.
- Editorial: Innovating public mental health: integrating digital therapeutics for comprehensive mood disorder management
- PO037 | TEMPO: A MOBILE HEALTH APPLICATION FOR PERSONALIZED MANAGEMENT OF HEMOPHILIA
- Developing a digital heart failure symptom management intervention using the preparation phase of the Multiphase Optimization StraTegy
- Anticoagulation management and valve-related outcomes after mechanical valve implantation in patients with Fontan palliation
BibTeX
@article{cavarretta2026role,
title = {{Role of digital health in the personalized management of heart failure due to Fontan failure: a case report}},
author = {Elena Cavarretta and Maria Teresa Quarta and Gianfranco Butera and Antonio Amodeo and Rachele Adorisio},
journal = {European Heart Journal. Case Reports},
year = {2026},
month = oct,
doi = {10.1093/ehjcr/ytag733},
url = {https://doi.org/10.1093/ehjcr/ytag733},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Role of digital health in the personalized management of heart failure due to Fontan failure: a case report
AU - Elena Cavarretta
AU - Maria Teresa Quarta
AU - Gianfranco Butera
AU - Antonio Amodeo
AU - Rachele Adorisio
PY - 2026
DA - 2026/10/07
JO - European Heart Journal. Case Reports
DO - 10.1093/ehjcr/ytag733
UR - https://doi.org/10.1093/ehjcr/ytag733
AB - Background: Heart failure (HF) represents a major cause of morbidity and mortality in patients with Fontan circulation. Chronic venous congestion, impaired preload, and limited cardiac output reserve make clinical assessment and intermittent invasive evaluations insufficient to capture early haemodynamic deterioration. Pharmacological treatment lack of robust evidence in this subgroup of patients. In this challenging setting, implantable invasive haemodynamic monitoring systems may provide continuous, real-life information capable of guiding personalized HF management. Case summary: A 26-year-old Fontan male developed protein losing enteropathy and recurrent hospitalizations for decompensated heart failure. Therefore, the patient was candidate to heart transplantation. Over time, episodes of acute HF increased with an escalating requirement of dosage of diuretics. At 22 years of age, another episode of acute decompensated HF prompted a catheter-based intervention with Fontan conduit re-dilatation and re-fenestration with an Atrial Flow Regulator (AFR) implant, and a pulmonary artery pressure monitoring system (CardioMEMS™) was deployed to telemonitor pulmonary artery pressures and adjust the diuretic therapy accordingly. Up to date, 4 years from the intervention, the use of this remote monitoring system was feasible and effective in tailoring medical therapy to prevent further hospitalizations for acute HF. The patient is in clinical follow-up with regular controls. Discussion: Systems allowing continuous or repeated assessment of haemodynamic status in real-life conditions may support personalized treatment adjustments, improve symptom control, and potentially reduce HF-related hospitalizations in patients with failing Fontan circulation.
SN - 2514-2119
ER -